样式: 排序: IF: - GO 导出 标记为已读
-
Metabolomic analysis of dietary‐restriction‐induced attenuation of sarcopenia in prematurely aging DNA repair‐deficient mice J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-05-01 Yupeng He, Wei Yang, Luojiao Huang, Marlien Admiraal‐van Mever, Rawi Ramautar, Amy Harms, Yvonne Rijksen, Renata M.C. Brandt, Sander Barnhoorn, Kimberly Smit, Dick Jaarsma, Peter Lindenburg, Jan H. J. Hoeijmakers, Wilbert P. Vermeij, Thomas Hankemeier
BackgroundSarcopenia is characterized by loss of skeletal muscle mass and function, and is a major risk factor for disability and independence in the elderly. Effective medication is not available. Dietary restriction (DR) has been found to attenuate aging and aging‐related diseases, including sarcopenia, but the mechanism of both DR and sarcopenia are incompletely understood.MethodsIn this study,
-
Concerted regulation of skeletal muscle metabolism and contractile properties by the orphan nuclear receptor Nr2f6 J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-29 Dimitrius Santiago P. S. F. Guimarães, Ninon M. F. Barrios, André Gustavo de Oliveira, David Rizo‐Roca, Maxence Jollet, Jonathon A.B. Smith, Thiago R. Araujo, Marcos Vinicius da Cruz, Emilio Marconato, Sandro M. Hirabara, André S. Vieira, Anna Krook, Juleen R. Zierath, Leonardo R. Silveira
BackgroundThe maintenance of skeletal muscle plasticity upon changes in the environment, nutrient supply, and exercise depends on regulatory mechanisms that couple structural and metabolic adaptations. The mechanisms that interconnect both processes at the transcriptional level remain underexplored. Nr2f6, a nuclear receptor, regulates metabolism and cell differentiation in peripheral tissues. However
-
DNA methylation of skeletal muscle function-related secretary factors identifies FGF2 as a potential biomarker for sarcopenia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-20 Jia-Wen Li, Zheng-Kai Shen, Yu-Shuang Lin, Zhi-Yue Wang, Mei-Lin Li, Hui-Xian Sun, Quan Wang, Can Zhao, Jin-Shui Xu, Xiang Lu, Wei Gao
Sarcopenia is characterized by progressive loss of muscle mass and function due to aging. DNA methylation has been identified to play important roles in the dysfunction of skeletal muscle. The aim of our present study was to explore the whole blood sample-based methylation changes of skeletal muscle function-related factors in patients with sarcopenia.
-
Protein-enriched soup and weekly exercise improve muscle health: A randomized trial in mid-to-old age with inadequate protein intake J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-20 Li-Ning Peng, Ming-Hsien Lin, Sung-Hua Tseng, Ko-Han Yen, Huei-Fang Lee, Fei-Yuan Hsiao, Liang-Kung Chen
Prior research has highlighted the synergistic impact of protein supplementation on muscle function post-exercise in adults; however, evidence supporting the combined effects were less robust and inconsistent on those with protein insufficiency. This investigation aims to explore efficacy of protein-enriched soup coupled with exercise on muscle health and metabolism in middle-aged and older adults
-
Differentially co‐expressed myofibre transcripts associated with abnormal myofibre proportion in chronic obstructive pulmonary disease J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-23 Joe W. Chiles, Ava C. Wilson, Rachel Tindal, Kaleen Lavin, Samuel Windham, Harry B. Rossiter, Richard Casaburi, Anna Thalacker‐Mercer, Thomas W. Buford, Rakesh Patel, J. Michael Wells, Marcas M. Bamman, Beatriz Y. Hanaoka, Mark Dransfield, Merry‐Lynn N. McDonald
BackgroundSkeletal muscle dysfunction is a common extrapulmonary manifestation of chronic obstructive pulmonary disease (COPD). Alterations in skeletal muscle myosin heavy chain expression, with reduced type I and increased type II myosin heavy chain expression, are associated with COPD severity when studied in largely male cohorts. The objectives of this study were (1) to define an abnormal myofibre
-
Metabolic phenotyping with computed tomography deep learning for metabolic syndrome, osteoporosis and sarcopenia predicts mortality in adults J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-23 Sang Wouk Cho, Seungjin Baek, Sookyeong Han, Chang Oh Kim, Hyeon Chang Kim, Yumie Rhee, Namki Hong
BackgroundComputed tomography (CT) body compositions reflect age‐related metabolic derangements. We aimed to develop a multi‐outcome deep learning model using CT multi‐level body composition parameters to detect metabolic syndrome (MS), osteoporosis and sarcopenia by identifying metabolic clusters simultaneously. We also investigated the prognostic value of metabolic phenotyping by CT model for long‐term
-
Mortality burden of pre‐treatment weight loss in patients with non‐small‐cell lung cancer: A systematic literature review and meta‐analysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-23 Philip D. Bonomi, Jeffrey Crawford, Richard F. Dunne, Eric J. Roeland, Karen E. Smoyer, Mohd Kashif Siddiqui, Thomas D. McRae, Michelle I. Rossulek, James H. Revkin, Lisa C. Tarasenko
Cachexia, with weight loss (WL) as a major component, is highly prevalent in patients with cancer and indicates a poor prognosis. The primary objective of this study was to conduct a meta‐analysis to estimate the risk of mortality associated with cachexia (using established WL criteria prior to treatment initiation) in patients with non‐small‐cell lung cancer (NSCLC) in studies identified through a
-
Improved therapeutic approach for spinal muscular atrophy via ubiquitination‐resistant survival motor neuron variant J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-23 Joonwoo Rhee, Jong‐Seol Kang, Young‐Woo Jo, Kyusang Yoo, Ye Lynne Kim, Sang‐Hyeon Hann, Yea‐Eun Kim, Hyun Kim, Ji‐Hoon Kim, Young‐Yun Kong
BackgroundZolgensma is a gene‐replacement therapy that has led to a promising treatment for spinal muscular atrophy (SMA). However, clinical trials of Zolgensma have raised two major concerns: insufficient therapeutic effects and adverse events. In a recent clinical trial, 30% of patients failed to achieve motor milestones despite pre‐symptomatic treatment. In addition, more than 20% of patients showed
-
Systematic druggable genome‐wide Mendelian randomization identifies therapeutic targets for sarcopenia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-22 Kang‐Fu Yin, Ting Chen, Xiao‐Jing Gu, Wei‐Ming Su, Zheng Jiang, Si‐Jia Lu, Bei Cao, Li‐Yi Chi, Xia Gao, Yong‐Ping Chen
BackgroundThere are no effective pharmacological treatments for sarcopenia. We aim to identify potential therapeutic targets for sarcopenia by integrating various publicly available datasets.MethodsWe integrated druggable genome data, cis‐eQTL/cis‐pQTL from human blood and skeletal muscle tissue, and GWAS summary data of sarcopenia‐related traits to analyse the potential causal relationships between
-
The prevalence patterns and risk factor profiles of poor muscle health and its associated components in multiethnic older Asians: The PIONEER study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-22 Preeti Gupta, Tai‐Anh Vu, Ryan E.K. Man, Eva K. Fenwick, Laura Tay, Ng Yee Sien, David Ng, Koh Hong Xiang Frederick, Eu‐Leong Yong, Samuel T.H. Chew, Ecosse L. Lamoureux
BackgroundWe aim to determine the multiethnic patterns of the prevalence and associated factors of poor muscle health and its associated components in older Chinese, Malays, and Indian Asian adults.MethodsWe included 2199 participants (mean age ± SD: 72.9 ± 8.3 years; 54.3% female) from the baseline assessment of the Population Health and Eye Disease Profile in Elderly Singaporeans (PIONEER; 2017–2022)
-
Exploring the optimal indicator of short‐term peridiagnosis weight dynamics to predict cancer survival: A multicentre cohort study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-22 Liangyu Yin, Ling Zhang, Long Li, Ming Liu, Jin Zheng, Aiguo Xu, Quanjun Lyu, Yongdong Feng, Zengqing Guo, Hu Ma, Jipeng Li, Zhikang Chen, Hui Wang, Zengning Li, Chunling Zhou, Xi Gao, Min Weng, Qinghua Yao, Wei Li, Tao Li, Hanping Shi, Hongxia Xu
BackgroundBody weight and its changes have been associated with cancer outcomes. However, the associations of short‐term peridiagnosis weight dynamics in standardized, clinically operational time frames with cancer survival remain largely unknown. This study aimed to screen for and evaluate the optimal indicator of short‐term peridiagnosis weight dynamics to predict overall survival (OS) in patients
-
Sarcopenia, adiposity and large discordance between cystatin C and creatinine‐based estimated glomerular filtration rate in patients with cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-22 Paul E. Hanna, Tianqi Ouyang, Ismail Tahir, Nurit Katz‐Agranov, Qiyu Wang, Lea Mantz, Ian Strohbehn, Daiana Moreno, Destiny Harden, James E. Dinulos, Duru Cosar, Harish Seethapathy, Justin F. Gainor, Sachin J. Shah, Shruti Gupta, David E. Leaf, Florian J. Fintelmann, Meghan E. Sise
BackgroundCreatinine‐based estimated glomerular filtration rate (eGFRCRE) may overestimate kidney function in patients with sarcopenia. While cystatin C‐based eGFR (eGFRCYS) is less affected by muscle mass, it may underestimate kidney function in patients with obesity. We sought to evaluate the relationship between body composition defined by computed tomography (CT) scans and discordance between creatinine
-
Metabolomics‐driven discovery of therapeutic targets for cancer cachexia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-22 Pengfei Cui, Xiaoyi Li, Caihua Huang, Donghai Lin
Cancer cachexia (CC) is a devastating metabolic syndrome characterized by skeletal muscle wasting and body weight loss, posing a significant burden on the health and survival of cancer patients. Despite ongoing efforts, effective treatments for CC are still lacking. Metabolomics, an advanced omics technique, offers a comprehensive analysis of small‐molecule metabolites involved in cellular metabolism
-
Association of endothelial dysfunction and peripheral arterial disease with sarcopenia in chronic kidney disease J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-22 Bang‐Gee Hsu, Chih‐Hsien Wang, Yu‐Hsien Lai, Chiu‐Huang Kuo, Yu‐Li Lin
BackgroundEndothelial dysfunction and peripheral arterial disease (PAD), which disturb skeletal muscle microperfusion, are highly prevalent in patients with chronic kidney disease (CKD). We evaluated the association of endothelial dysfunction and PAD with sarcopenia in patients with non‐dialysis CKD.MethodsThis cross‐sectional study included 420 patients with stages 3–5 non‐dialysis CKD aged 69.0 ±
-
Accelerated sarcopenia precedes learning and memory impairments in the P301S mouse model of tauopathies and Alzheimer's disease J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-22 Savannah Longo, María Laura Messi, Zhong‐Min Wang, William Meeker, Osvaldo Delbono
BackgroundAlzheimer's disease (AD) impairs cognitive functions and peripheral systems, including skeletal muscles. The PS19 mouse, expressing the human tau P301S mutation, shows cognitive and muscular pathologies, reflecting the central and peripheral atrophy seen in AD.MethodsWe analysed skeletal muscle morphology and neuromuscular junction (NMJ) through immunohistochemistry and advanced image quantification
-
Cross-sectional interactive associations of physical activity and sedentary behaviour with physical capacity across adulthood J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-18 Jérémy Raffin, Yves Rolland, Mylène Aubertin-Leheudre, Jaqueline Aragoni da Silva, Sophie Guyonnet, Fabien Pillard, Bruno Vellas, Philipe de Souto Barreto
The way physical activity (PA) and sedentary behaviour (SB) independently and interactively modify the age-related decline in physical capacity remains poorly understood. This cross-sectional study investigated the independent and interactive associations of PA and SB with physical function and performance throughout the adult life course.
-
Lean body mass and the cardiorespiratory phenotype: An ethnic-specific relationship in Hans Chinese women and men J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-17 Meihan Guo, Candela Diaz-Canestro, Nicola Riccardo Pugliese, Francesco Paneni, David Montero
Lean body mass (LBM) and the functional capacity of cardiovascular (CV) and respiratory systems constitute a female-specific relationship in European–American individuals. Whether this recent finding be extrapolated to the world's largest ethnic group, that is, Hans Chinese (HC, a population characterized by low LBM), is unknown.
-
Adiponectin-to-leptin ratio and incident chronic kidney disease: Sex and body composition-dependent association J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-17 Hye-Sun Park, Sang Ho Park, Yeseul Seong, Hyo Jeong Kim, Hoon Young Choi, Yumie Rhee, Hyeong Cheon Park, Jong Hyun Jhee
The association between the adiponectin-to-leptin ratio (A/L ratio) and the risk of incident chronic kidney disease (CKD) is poorly understood. This study aimed to investigate the association between A/L ratio and the risk of incident CKD and to examine whether such a relationship varied according to sex and body composition.
-
Hepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-17 Paige C. Arneson-Wissink, Heike Mendez, Katherine Pelz, Jessica Dickie, Alexandra Q. Bartlett, Beth L. Worley, Stephanie M. Krasnow, Robert Eil, Aaron J. Grossberg
Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate
-
Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-13 Harmen Reyngoudt, Pierre‐Yves Baudin, Ericky Caldas de Almeida Araújo, Damien Bachasson, Jean‐Marc Boisserie, Kubéraka Mariampillai, Mélanie Annoussamy, Yves Allenbach, Jean‐Yves Hogrel, Pierre G. Carlier, Benjamin Marty, Olivier Benveniste
BackgroundFinding sensitive clinical outcome measures has become crucial in natural history studies and therapeutic trials of neuromuscular disorders. Here, we focus on 1‐year longitudinal data from quantitative magnetic resonance imaging (MRI) and phosphorus magnetic resonance spectroscopy (31P MRS) in a placebo‐controlled study of sirolimus for inclusion body myositis (IBM), also examining their
-
Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapy J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-13 Jeong Yun Jang, Dongryul Oh, Jae Myoung Noh, Jong‐Mu Sun, Hong Kwan Kim, Young Mog Shim
BackgroundWe aimed to identify the impact of muscle mass on locally advanced oesophageal cancer (LAEC) in elderly patients receiving neoadjuvant chemoradiation therapy (NACRT).MethodsWe reviewed the medical records of 345 patients diagnosed with LAEC who underwent NACRT and surgery. Physical variables, including height, weight, skeletal muscle mass, and laboratory values, were obtained before and after
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-05
No abstract is available for this article.
-
Glycative stress inhibits hypertrophy and impairs cell membrane integrity in overloaded mouse skeletal muscle J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-05 Tatsuro Egawa, Takeshi Ogawa, Takumi Yokokawa, Kohei Kido, Ryota Iyama, Haiyu Zhao, Eriko Kurogi, Katsumasa Goto, Tatsuya Hayashi
BackgroundGlycative stress, characterized by the formation and accumulation of advanced glycation end products (AGEs) associated with protein glycation reactions, has been implicated in inducing a decline of muscle function. Although the inverse correlation between glycative stress and muscle mass and strength has been demonstrated, the underlying molecular mechanisms are not fully understood. This
-
Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour‐bearing mice J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-04 Isabelle S. Massart, Axell‐Natalie Kouakou, Nathan Pelet, Pascale Lause, Olivier Schakman, Audrey Loumaye, Michel Abou‐Samra, Louise Deldicque, Laure B. Bindels, Sonia M. Brichard, Jean‐Paul Thissen
BackgroundCancer cachexia is a life‐threatening, inflammation‐driven wasting syndrome that remains untreatable. Adiponectin, the most abundant adipokine, plays an important role in several metabolic processes as well as in inflammation modulation. Our aim was to test whether administration of AdipoRon (AR), a synthetic agonist of the adiponectin receptors, prevents the development of cancer cachexia
-
Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-02 Ambarish Pandey, Kershaw V. Patel, Matthew W. Segar, Colby Ayers, Jennifer Linge, Olof D. Leinhard, Stefan D. Anker, Javed Butler, Subodh Verma, Parag H. Joshi, Ian J. Neeland
BackgroundExcess muscle fat is observed in obesity and associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat and adverse muscle composition is unknown.MethodsThis is a pre‐specified secondary analysis of a randomized, double‐blind, placebo‐controlled trial that examined the effects
-
Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-01 Nadia M. Anabtawi, Monica Sai Pasala, Alyssa A. Grimshaw, Prakash Kharel, Susan Bal, Kelly Godby, Ashmita Siwakoti, Thomas W. Buford, Smita Bhatia, Luciano J. Costa, Grant R. Williams, Smith Giri
BackgroundLow skeletal muscle mass (LSMM) and/or, function associated with an increased risk of treatment‐related toxicities and inferior overall survival (OS) among adults with solid malignancies. However, the association between LSMM and treatment‐related toxicities among adults with haematologic malignancies remains unclear.MethodsUsing a pre‐published protocol (CRD42020197814), we searched seven
-
Mapping the causal associations of cytokines with sarcopenia and aging traits: Evidence from bidirectional Mendelian randomization J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-04-01 Mingchong Liu, Xiao Fu, Daqian Yu, Meng Li, Yutao Pan, Chensong Yang, Guixin Sun
BackgroundCytokines and growth factors may serve as a bridge in studying the causal relationships between inflammaging and sarcopenia due to their roles in inflammaging. In this study, we aim to explore the causal association of cytokines with sarcopenia and aging traits and further identify the significant inflammation factors.MethodsBidirectional Mendelian randomization (MR) analysis was used to
-
Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-29 Marianne J. Hjermstad, Gunnhild Jakobsen, Jann Arends, Trude Balstad, Leo R. Brown, Asta Bye, Andrew J.S. Coats, Olav F. Dajani, Ross D. Dolan, Marie T. Fallon, Christine Greil, Alexandra Grzyb, Stein Kaasa, Lisa H. Koteng, Anne M. May, James McDonald, Inger Ottestad, Iain Philips, Eric J. Roeland, Judith Sayers, Melanie R. Simpson, Richard J.E. Skipworth, Tora S. Solheim, Mariana S. Sousa, Ola M.
The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing, and perceptions of care, represent important measures of efficacy. This review describes the frequency, variety, and reporting of QOL endpoints used in cancer cachexia clinical trials. Electronic literature searches were performed in Medline, Embase
-
The regulation of MFG‐E8 on the mitophagy in diabetic sarcopenia via the HSPA1L‐Parkin pathway and the effect of D‐pinitol J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-30 Wenqian Zhao, Bin Zhao, Xinyue Meng, Baoying Li, Yajuan Wang, Fei Yu, Chunli Fu, Xin Yu, Xiaoli Li, Chaochao Dai, Jie Wang, Haiqing Gao, Mei Cheng
BackgroundDiabetic sarcopenia is a disease‐related skeletal muscle disorder that causes progressive symptoms. The complete understanding of its pathogenesis is yet to be unravelled, which makes it difficult to develop effective therapeutic strategies. This study investigates how MFG‐E8 affects mitophagy and the protective role of D‐pinitol (DP) in diabetic sarcopenia.MethodsIn vivo, streptozotocin‐induced
-
The effect of low birth weight as an intrauterine exposure on the early onset of sarcopenia through possible molecular pathways J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-30 Dilek Celik, Manuela Campisi, Luana Cannella, Sofia Pavanello
Sarcopenia, a musculoskeletal disease characterized by the progressive loss of skeletal muscle mass, strength, and physical performance, presents significant challenges to global public health due to its adverse effects on mobility, morbidity, mortality, and healthcare costs. This comprehensive review explores the intricate connections between sarcopenia and low birth weight (LBW), emphasizing the
-
Leukocyte telomere length is associated with MRI‐thigh fat‐free muscle volume: data from 16 356 UK Biobank adults J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-30 Ben Kirk, Chia‐Ling Kuo, Peiran Liu, Meiruo Xiang, Jacob E. Earp, Jatupol Kositsawat, George A. Kuchel, Gustavo Duque
BackgroundTelomere attrition may share common biological mechanisms with bone and muscle loss with aging. Here, we investigated the association between these hallmarks of aging using data from UK Biobank, a large observational study.MethodsLeukocyte telomere length (LTL as T/S ratio) was measured using a multiplex qPCR assay at baseline (2006–2010). Bone mineral density (whole body and regional; via
-
ADAR2 deficiency ameliorates non‐alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1 J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-27 Mei‐Lang Kung, Tai‐Hua Yang, Chia‐Chi Lin, Jia‐Yun Ho, Tzu‐Chi Hung, Chih‐Hsiang Chang, Kuan‐Wen Huang, Chien‐Chin Chen, Yun‐Wen Chen
BackgroundNon‐alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, which is commonly associated with NAFLD. Adenosine‐to‐inosine editing, catalysed by adenosine deaminase acting on RNA (ADAR), is an important post‐transcriptional modification
-
Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials? J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-27 Ross Valaire, Frances Garden, Valentina Razmovski‐Naumovski
BackgroundCachexia is prevalent in gastrointestinal cancers and worsens patient outcomes and chemotherapy compliance. We examined to what extent registered gastrointestinal cancer chemotherapy clinical trials record measures and related symptoms of cachexia as outcomes, and whether these were associated with trial characteristics.MethodsFour public trial registries (2012–2022) were accessed for Phase
-
Lack of vitamin D signalling in mesenchymal progenitors causes fatty infiltration in muscle J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-27 Tohru Hosoyama, Minako Kawai‐Takaishi, Hiroki Iida, Yoko Yamamoto, Yuko Nakamichi, Tsuyoshi Watanabe, Marie Takemura, Shigeaki Kato, Akiyoshi Uezumi, Yasumoto Matsui
BackgroundRecent studies have indicated the importance of muscle quality in addition to muscle quantity in sarcopenia pathophysiology. Intramuscular adipose tissue (IMAT), which originates from mesenchymal progenitors (MPs) in adult skeletal muscle, is a key factor affecting muscle quality in older adults, suggesting that controlling IMAT formation is a promising therapeutic strategy for sarcopenia
-
The evolution and impact of sarcopenia in severe aplastic anaemia survivors following allogeneic haematopoietic cell transplantation J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-25 Dandan Chen, Zhaohu Yuan, Yuan Guo, Weifeng Liu, Zixuan Cheng, Lihua Ye, Wenjian Mo, Xinhua Wei
BackgroundSarcopenia is a potential risk factor for adverse outcomes in haematopoietic cell transplantation (HSCT) recipients. We aimed to explore longitudinal body changes in muscle and adipose mass and their prognostic value in allogeneic HSCT‐treated severe aplastic anaemia (SAA) patients.MethodsWe retrospectively analysed consecutive SAA patients who underwent allogeneic HSCT between January 2017
-
Standardizing trait selection in Mendelian randomization studies concerning sarcopenia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-23 Mingchong Liu, Pengcheng Chen, Chensong Yang, Guixin Sun
Mendelian randomization (MR) is a method of using genetic variants as instrumental variables to assess the causal effect of exposures on disease outcomes. MR has gained increasing attention in the field of genetic epidemiology and has been applied to explore the causal associations in various diseases, including sarcopenia.1 Traditional observational studies are often limited in their ability to demonstrate
-
Metabolic syndrome and cardiovascular disease in cancer survivors J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-22 Kensuke Ueno, Hidehiro Kaneko, Yuta Suzuki, Akira Okada, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro
BackgroundThe risk of subsequent cardiovascular disease (CVD) is high in cancer survivors. Although metabolic syndrome is an established risk factor for CVD, its association with cancer survivors has not yet been established. This study aimed to clarify whether metabolic syndrome is associated with subsequent CVD risk in patients with cancer using a nationwide epidemiological dataset.MethodsWe retrospectively
-
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-19 John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon L. Lubaczewski, Danna M. Breen, Magdalena A. Harrington, Ira Jacobs, Ruolun Qiu, James Revkin, Michelle I. Rossulek, Aditi R. Saxena
BackgroundCancer cachexia is a multifactorial metabolic wasting syndrome characterized by anorexia, unintentional loss of weight involving both skeletal muscle and adipose tissues, progressive functional impairment and reduced survival. Therapeutic strategies for this serious condition are very limited. Growth differentiation factor 15 (GDF‐15) is a cytokine that is implicated in cancer cachexia and
-
Cancer anorexia‐cachexia syndrome is characterized by more than one inflammatory pathway J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-14 Bruno Gagnon, Jessica Murphy, David Simonyan, Claudia A. Penafuerte, Jacinthe Sirois, Martin Chasen, Michel L. Tremblay
BackgroundThe interdependence of cytokines and appetite‐modifying hormones implicated in cancer anorexia‐cachexia syndrome (CACS) remains unclear. This study aimed to regroup these cytokines and hormones into distinct inflammatory (or non‐inflammatory) pathways and determine whether these pathways can classify patients with CACS phenotypes.MethodsClinical characteristics of 133 patients [61.7% male;
-
The relationship between weight gain during chemotherapy and outcomes in patients with advanced non‐small cell lung cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-12 Eric J. Roeland, Florian J. Fintelmann, Fiona Hilton, Ruoyong Yang, Ed Whalen, Lisa Tarasenko, Roberto A. Calle, Philip D. Bonomi
BackgroundThis post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non‐small cell lung cancer (NSCLC) receiving first‐line platinum‐based chemotherapy.MethodsData were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first
-
Frailty phenotype as mediator between systemic inflammation and osteoporosis and fracture risks: A prospective study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-12 Dongsheng Di, Haolong Zhou, Zhangbo Cui, Jianli Zhang, Qian Liu, Tingting Yuan, Tingting Zhou, Xiao Luo, Danyang Ling, Qi Wang
BackgroundSystemic inflammation and frailty have been implicated in osteoporosis (OP) and fracture risks; however, existing evidence remains limited and inconclusive. This study aimed to assess the associations of systemic inflammation and frailty phenotype with incident OP and fracture and to evaluate the mediating role of frailty phenotype.MethodsThe present study analysed data from the UK Biobank
-
Comment on “A promising prognostic grading system incorporating weight loss and inflammation in patients with advanced cancer” by Zhang et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-12 Josh McGovern, Donald C. McMillan
Dear Editor, We read the manuscript ‘A promising prognostic grading system incorporating weight loss and inflammation in patients with advanced cancer’ by Zhang and co-workers with considerable interest. The authors are to be congratulated for carrying out a large multicentre prospective cohort study of 11 423 patients with advanced cancer that examined the prognostic value of the combination of weight
-
Control of muscle satellite cell function by specific exercise-induced cytokines and their applications in muscle maintenance J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-20 Qian Guo, Qing Luo, Guanbin Song
Exercise is recognized to play an observable role in improving human health, especially in promoting muscle hypertrophy and intervening in muscle mass loss-related diseases, including sarcopenia. Recent rapid advances have demonstrated that exercise induces the release of abundant cytokines from several tissues (e.g., liver, muscle, and adipose tissue), and multiple cytokines improve the functions
-
Bed-rest and exercise remobilization: Concurrent adaptations in muscle glucose and protein metabolism J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-12 Natalie F. Shur, Elizabeth J. Simpson, Hannah Crossland, Despina Constantin, Sally M. Cordon, Dumitru Constantin-Teodosiu, Francis B. Stephens, Matthew S. Brook, Philip J. Atherton, Kenneth Smith, Daniel J. Wilkinson, Olivier E. Mougin, Christopher Bradley, Ian A. Macdonald, Paul L. Greenhaff
Bed-rest (BR) of only a few days duration reduces muscle protein synthesis and induces skeletal muscle atrophy and insulin resistance, but the scale and juxtaposition of these events have not been investigated concurrently in the same individuals. Moreover, the impact of short-term exercise-supplemented remobilization (ESR) on muscle volume, protein turnover and leg glucose uptake (LGU) in humans is
-
The optimal cut-off value of five-time chair stand test for assessing sarcopenia among Chinese community-dwelling older adults J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-11 Yu-Hua Li, Xiu-Hua Wang, Shi Ya, Huang Jiaoling, Nan Hua
The five-time chair stand test (5CST) as an indicator of muscle strength and physical function is the first step in assessing sarcopenia. We aimed to determine the optimal cut-off value of the 5CST for assessing older adults with sarcopenia in the Chinese community.
-
Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-11 Ola Magne Vagnildhaug, Trude R. Balstad, Inger Ottestad, Asta Bye, Christine Greil, Jann Arends, Vickie Baracos, Leo R. Brown, Olav F. Dajani, Ross D. Dolan, Marie Fallon, Eilidh Fraser, Aleksandra Grzyb, Marianne J. Hjermstad, Gunnhild Jakobsen, Stein Kaasa, James McDonald, Iain Philips, Judith Sayers, Melanie R. Simpson, Mariana S. Sousa, Richard J.E. Skipworth, Barry J.A. Laird, Tora S. Solheim
There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and evaluate endpoints used to assess appetite and dietary intake in cancer cachexia clinical trials. A search for studies published from 1 January 1990 until 2 June 2021 was conducted
-
Chronic aryl hydrocarbon receptor activity impairs muscle mitochondrial function with tobacco smoking J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-09 Liam F. Fitzgerald, Jacob Lackey, Ahmad Moussa, Sohan V. Shah, Ana Maria Castellanos, Shawn Khan, Martin Schonk, Trace Thome, Zachary R. Salyers, Nishka Jakkidi, Kyoungrae Kim, Qingping Yang, Russell T. Hepple, Terence E. Ryan
Accumulating evidence has demonstrated that chronic tobacco smoking directly contributes to skeletal muscle dysfunction independent of its pathological impact to the cardiorespiratory systems. The mechanisms underlying tobacco smoke toxicity in skeletal muscle are not fully resolved. In this study, the role of the aryl hydrocarbon receptor (AHR), a transcription factor known to be activated with tobacco
-
Chronic hypoxia impairs skeletal muscle repair via HIF-2α stabilization J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-09 Amelia Yin, Wenyan Fu, Anthony Elengickal, Joonhee Kim, Yang Liu, Anne Bigot, Kamal Mamchaoui, Jarrod A. Call, Hang Yin
Chronic hypoxia and skeletal muscle atrophy commonly coexist in patients with COPD and CHF, yet the underlying physio-pathological mechanisms remain elusive. Muscle regeneration, driven by muscle stem cells (MuSCs), holds therapeutic potential for mitigating muscle atrophy. This study endeavours to investigate the influence of chronic hypoxia on muscle regeneration, unravel key molecular mechanisms
-
Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-08 Min Woo Lee, Sun Kyung Jeon, Woo Hyun Paik, Jeong Hee Yoon, Ijin Joo, Jeong Min Lee, Sang Hyub Lee
Sarcopenia or visceral adipose tissue has been reported to be related to pancreatic cancer prognosis. However, clinical relevance of the comprehensive analysis of body compositions and their longitudinal changes is lacking. This study analysed the association between body composition changes after chemotherapy and survival in patients with metastatic pancreatic cancer.
-
Longitudinal association between muscle and bone loss: Results of US and Japanese cohort studies J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-08 Yusuke Osawa, Yang An, Yukiko Nishita, Yasumoto Matsui, Marie Takemura, Eleanor M. Simonsick, Hiroshi Shimokata, Rei Otsuka, Hidenori Arai, Luigi Ferrucci
Muscle and bone are physiologically interconnected, but joint changes of muscle and bone with aging, and whether the muscle-bone changes are different by sex and by country has been little studied. We examined longitudinal associations of bone mineral density (BMD) and muscle mass or muscle strength in community-dwelling 65 years or older in the United States and Japan.
-
Correction to ‘Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease’ by Lakshman Kumar et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-07
In Preeti Lakshman Kumar, Ava C. Wilson, Alison Rocco, Michael H. Cho, Emily Wan, Brian D. Hobbs, George R. Washko, Victor E. Ortega, Stephanie A. Christenson, Xingnan Li, J. Michael Wells, Surya P. Bhatt, Dawn L. DeMeo, Sharon M. Lutz, Harry Rossiter, Richard Casaburi, Stephen I. Rennard, David A. Lomas, Wassim W. Labaki, Ruth Tal-Singer, Russel P. Bowler, Craig P. Hersh, Hemant K. Tiwari, Mark Dransfield
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-01
No abstract is available for this article.
-
R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-01 Sophia E. Chrysostomou, Sandra Eder, Isabella Pototschnig, Anna-Lena Mayer, Martina Derler, Marion Mussbacher, Silvia Schauer, Dongxu Zhang, Dongmei Yan, Gennie Liu, Gerald Hoefler, Thomas Weichhart, Paul W. Vesely, Lingbing Zhang, Martina Schweiger
Cancer-associated cachexia (CAC) is a debilitating syndrome associated with poor quality of life and reduced life expectancy of cancer patients. CAC is characterized by unintended body weight reduction due to muscle and adipose tissue loss. A major hallmark of CAC is systemic inflammation. Several non-steroidal anti-inflammatory drugs (NSAIDs) have been suggested for CAC treatment, yet no single medication
-
Influence of skeletal muscle and intermuscular fat on postoperative complications and long-term survival in rectal cancer patients J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-31 Tong Nie, Feihong Wu, Yixin Heng, Wentai Cai, Zhihao Liu, Le Qin, Yinghao Cao, Chuansheng Zheng
The body composition of patients with rectal cancer potentially affects postoperative outcomes. This study explored the correlations between skeletal muscle and adipose tissue quantified by computed tomography (CT) with postoperative complications and long-term prognosis in patients with rectal cancer after surgical resection.
-
The burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-30 Hsi-Yu Lai, Shih-Tsung Huang, Stefan D. Anker, Stephan von Haehling, Masahiro Akishita, Hidenori Arai, Liang-Kung Chen, Fei-Yuan Hsiao
Frailty often coexists with heart failure (HF), which significantly aggravates the clinical outcomes of older adults. However, studies investigating the interplay between frailty and HF in older adults are scarce. We aimed to assess the prevalence of frailty using the cumulative deficit approach and evaluate the impacts of frailty on health utilization, use of HF-related medications and adverse clinical
-
Muscle parameters in fragility fracture risk prediction in older adults: A scoping review J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-29 Colin Vendrami, Enisa Shevroja, Elena Gonzalez Rodriguez, Guillaume Gatineau, Jolanda Elmers, Jean-Yves Reginster, Nicholas C. Harvey, Olivier Lamy, Didier Hans
Half of osteoporotic fractures occur in patients with normal/osteopenic bone density or at intermediate or low estimated risk. Muscle measures have been shown to contribute to fracture risk independently of bone mineral density. The objectives were to review the measurements of muscle health (muscle mass/quantity/quality, strength and function) and their association with incident fragility fractures
-
Sizing and mending of appendicular muscle mass for hydration during the 12-lead electrocardiogram: True incidence of sarcopenia in heart failure J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-26 Falko Skrabal, Steven B. Heymsfield, Katharina Skrabal, Thomas Weber, Friedrich Fruhwald, Jana Windhaber, Samy Mady
Our aim was to develop and evaluate a method for the measurement of muscle mass during the 12-channel electrocardiogram (ECG), to determine the incidence of sarcopenia in patients with overhydration and to correct it for congestion.
-
RORα–GABP–TFAM axis alleviates myosteatosis with fatty atrophy through reinforcement of mitochondrial capacity J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-25 Hyeon-Ji Kim, Sang-Heon Lee, Cheolhee Jeong, Yong-Hyun Han, Mi-Ock Lee
Fat infiltration in muscle, called ‘myosteatosis’, precedes muscle atrophy, which subsequently results in sarcopenia. Myosteatosis is frequently observed in patients with nonalcoholic fatty liver disease (NAFLD). We have previously reported that retinoic acid receptor-related orphan receptor-α (RORα) regulates mitochondrial dynamics and mitophagy in hepatocytes, resulting in an alleviation of NAFLD
-
Exploring the impact of short daily haemodialysis on muscle strength and bone health in end-stage kidney disease patients J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-25 Fernanda Silveira Tavares, Hugo de Luca Corrêa, Kenneth R. Wilund, Lysleine Alves Deus, Thais Branquinho de Araújo, Carmen Tzanno-Martins, Vitória Marra da Motta Vilalva Mestrinho, Rafael Lavarini dos Santos, Andrea Lucena Reis, Fernando Honorato Souza, Luiz Roberto de Sousa Ulisses, Helen Souto Siqueira Cardoso, Istênio José Fernandes Pascoal, Valéria Cunha Campos Guimarães, Lucy de Oliveira Gomes
Short-daily haemodialysis (SDH) has been strongly recommended over conventional haemodialysis (CHD) for end-stage kidney disease patients, though few studies have directly compared the effects of these two haemodialysis (HD) modalities on clinical variables related to patient's health.
-
CREG1 deficiency impaired myoblast differentiation and skeletal muscle regeneration J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-25 Haixu Song, Xiaoxiang Tian, Lianqi He, Dan Liu, Jiayin Li, Zhu Mei, Ting Zhou, Chunying Liu, Jiaqi He, Xiaodong Jia, Zheming Yang, Chenghui Yan, Yaling Han
CREG1 (cellular repressor of E1A-stimulated genes 1) is a protein involved in cellular differentiation and homeostasis regulation. However, its role in skeletal muscle satellite cells differentiation and muscle regeneration is poorly understood. This study aimed to investigate the role of CREG1 in myogenesis and muscle regeneration.